Frazier Life Sciences Management’s Revolution Medicines RVMD Stock Holding History

Frazier Life Sciences Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.7M	Sell	675,686 -121,769	-15%	-$12.3M	1.69%	15
2025 Q4	$63.5M	Sell	797,455 -200,000	-20%	-$13.1M	1.71%	15
2025 Q3	$46.6M	Hold	997,455	–	–	1.4%	18
2025 Q2	$36.7M	Hold	997,455	–	–	1.47%	16
2025 Q1	$35.3M	Hold	997,455	–	–	1.61%	16
2024 Q4	$43.6M	Hold	997,455	–	–	1.81%	15
2024 Q3	$45.2M	Hold	997,455	–	–	1.81%	17
2024 Q2	$38.7M	Hold	997,455	–	–	1.81%	16
2024 Q1	$32.1M	Hold	997,455	–	–	1.36%	24
2023 Q4	$28.6M	Hold	997,455	–	–	1.53%	17
2023 Q3	$27.6M	Buy	997,455 +142,971	+17%	+$4.24M	1.83%	17
2023 Q2	$22.9M	Hold	854,484	–	–	1.37%	18
2023 Q1	$18.5M	Buy	+854,484	New	+$21M	1.34%	21

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Frazier Life Sciences Management's RVMD Position: Q1 2026 in Review

Frazier Life Sciences Management reduced its Revolution Medicines (RVMD) stake by 15% in Q1 2026, selling an estimated $12.3M and leaving 675,686 shares worth $65.7M. The position accounts for 1.69% of the portfolio, ranked #15.

Frazier Life Sciences Management first reported a position in RVMD in Q1 2023 and has held it in 13 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

Frazier Life Sciences Management held 675,686 shares of Revolution Medicines worth $65.7M as of Q1 2026.
Frazier Life Sciences Management sold 121,769 Revolution Medicines shares in Q1 2026, an estimated $12.3M.
Revolution Medicines made up 1.69% of Frazier Life Sciences Management's portfolio in Q1 2026, its #15 holding.
Frazier Life Sciences Management first reported a position in Revolution Medicines in Q1 2023 and has held it in 13 quarters since.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.